https://www.selleckchem.com/pr....oducts/enarodustat.h
Copyright © 2020 Colas, Hassoun and Magnan.Background New oral prostacyclin therapies and prostacyclin agonists have become available for the treatment of pulmonary arterial hypertension (PAH). However, methods for transitioning between oral, inhaled, and parenteral formulations are not well-established, except in the form of case reports and case series. Collectively, these emphasize the lack of a standardized process and approach in transitioning patients between PAH prostanoid therapies. In this case series, we report our experie
Like
Comment
Share
